Bright Minds Biosciences (DRUG) Receivables - Other (2022 - 2025)

Bright Minds Biosciences (DRUG) posted Receivables - Other of -$113645.2 for Q2 2025, down 191.65% on a QoQ basis from $123994.7 in Q1 2025.

Bright Minds Biosciences (DRUG) Receivables - Other (2022 - 2025) Analysis & Trends

Bright Minds Biosciences' Receivables - Other history runs 4 years deep, the most recent figure standing at -$113645.2 for Q2 2025.

Quarterly Receivables - Other changed N/A year-over-year to -$113645.2 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was -$113645.2 (changed N/A YoY) and the FY2022 annual result came in at $31636.7, changed N/A from the prior year.
Receivables - Other was -$113645.2 for Q2 2025 at Bright Minds Biosciences, down from $123994.7 in the prior quarter.
Across five years, Receivables - Other topped out at $401891.4 in Q1 2024 and bottomed at -$113645.2 in Q2 2025.
A 4-year average of $76501.7 and a median of $30716.9 in 2023 frame the typical range for Receivables - Other.
Annual changes were most pronounced in 2024 — Receivables - Other surged 1216.79% — and 2025, when it slumped 69.15%.
Bright Minds Biosciences' Receivables - Other stood at $30397.1 in 2022, then grew by 1.05% to $30716.9 in 2023, then surged by 1208.37% to $401891.4 in 2024, then slumped by 128.28% to -$113645.2 in 2025.
Business Quant data shows DRUG's Receivables - Other at -$113645.2 in Q2 2025, $123994.7 in Q1 2025, and $401891.4 in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Bright Minds Biosciences	498.53 Mn	498.53 Mn	-

Download Data